New developments in the management of vulvovaginal atrophy: a comprehensive overview.
Expert Opin Pharmacother
; 24(5): 599-616, 2023 Apr.
Article
em En
| MEDLINE
| ID: mdl-36951262
ABSTRACT
INTRODUCTION:
Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount. AREAS COVERED Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections. PubMed searches were carried out between 1 march 2022 and 15 October 2022.Low dose vaginal estriol seems safe, efficient, and could be used in patients with contraindications for steroid hormones such as women with a history of breast cancer, and should therefore be considered as first choice hormonal treatment, when non-hormonal treatments fail. New estrogens, androgens, and several Selective Estrogen Receptor Modulators (SERMs) are being developed and tested. Intravaginal Hyaluronic Acid (HA) or Vit D can help women who can't or don't want to use hormones. EXPERT OPINION Proper treatment is not possible without a correct and full diagnosis, including microscopy of the vaginal fluid. Low dose vaginal estrogen treatment, especially with estriol, is very efficient and is preferred in most women with VVA. Oral ospemifene and vaginal dihydroepiandrosterone (DHEA) are now considered efficient and safe alternative therapies for VVA. More safety data are waited for several SERMs and for a newly introduced estrogen estetrol (E4), although so far no major side effects were seen from these drugs. Indications for laser treatments are questionable.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Vaginais
/
Moduladores Seletivos de Receptor Estrogênico
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article